# A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BCX17725

> **NCT06539507** · PHASE1 · RECRUITING · sponsor: **BioCryst Pharmaceuticals** · enrollment: 78 (estimated)

## Conditions studied

- Netherton Syndrome

## Interventions

- **DRUG:** BCX17725
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06539507
- **Lead sponsor:** BioCryst Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-26
- **Primary completion:** 2026-10
- **Final completion:** 2026-12
- **Target enrollment:** 78 (ESTIMATED)
- **Last updated:** 2026-03-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06539507

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06539507, "A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BCX17725". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06539507. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*